The Group’s associate company, ADOR Diagnostics (“ADOR”), which is creating the NATlab rapid molecular diagnostics platform, is pleased to announce the appointment of Dr. Eran Zahavy as its CEO. ADOR is a leading provider of real-time technologies for networking solutions and medical laboratory systems.
Dr. Eran Zahavy has over 20 years of management experience in both public and private bioscience organisations.
This includes positions like Head of Innovation at the Israel Institute for Biological Research and R&D Manager for Biological Pathogens Diagnostics (“IIBR”).
He directed the creation of the BriLife COVID-19 vaccine during the pandemic at IIBR in association with NRx Pharmaceuticals, a US-based company.
Other positions held by the CTO include those of CTO of TACount, a developer of imaging-based microbiological testing technology, and scientific advisor to Longliv Ventures, a strategic investor in health-tech start-ups and a member of the CK Hutchison Holdings Group. Hutchison Kinrot operates a technology incubator in Israel and is a seed investor in water and cleantech-related technologies.
Dr. Zahavy has recently held the positions of Senior Scientific Consultant to ADOR and BATM’s Adaltis diagnostics business and CTO of the Group’s Bio-Medical Division.
He has played a key role in the group’s molecular diagnostics operations during this time.
Dr. Zahavy completed postdoctoral fellowships at the University of Texas in Austin and the University of California at San Diego before earning his PhD in Chemistry and Biophysics from the Hebrew University.
Along with patents, he has more than 40 peer-reviewed scholarly articles to his credit.
The NATlab system is a molecular diagnostics platform being developed by ADOR that offers quick detection of pathogens from sample to answer using the isothermal amplification (RCA) method.
The NATlab device uses a single cartridge to test for many pathogens, with various cartridges created for various infectious disease panels, including those for meningitis, respiratory disorders, STIs, and more.
The Group is also collaborating with the Stop TB Partnership to create a method for the quick and thorough diagnosis of tuberculosis utilising ADOR and Adaltis.
